Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
The DOI matches its Crossref record.
Abstract
The integrin receptor alphavbeta3 has been shown to play a critical role in several distinct processes, such as angiogenesis, osteoclast-mediated bone resorption and tumor metastasis. Its expression is upregulated in newly synthesized blood vessels produced in response to a variety of tumors and purified angiogenic factors. Studies show that alphavbeta3 is a critical target downstream from perhaps all angiogcnic factors. Proof-of-principle that alphavbeta3 antagonists such as monoclonal antibodies and small molecules block angiogenesis and tumor growth has been obtained in several animal models. Many endogenous inhibitors of angiogenesis such as angiostatin, endostatin and tumstatin seem to work through the alphavbeta3 receptor further emphasizing the critical role of this receptor in angiogenesis. In addition, the alphavbeta3 receptor has been clearly implicated in several pathological processes such as rheumatoid arthritis, osteoporosis, and metastasis of prostate cancer to bone. Thus alphavbeta3 may prove to be an important target for pharmacological intervention in more than one clinical setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The critical nature of integrin binding to angiogenesis is also noted in other situations such as embryogenesis, where inhibition of b 1 integrins interfere with the development of the embryonic vasculature 63 and in oncology, where integrin inhibitors are employed to inhibit tumor angiogenesis.”
From Interactions between extracellular matrix and growth factors in wound healing (2009) · cites this paper as [64]
Citations
Cited by
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
Presta, M., Dell’Era, P., Mitola, S., Moroni, E., Ronca, R., & Rusnati, M. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.004 · Cited by 1,261
Interactions between extracellular matrix and growth factors in wound healing
Schultz, G. S., & Wysocki, A. (2009) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2009.00466.x · Cited by 1,126
“The critical nature of integrin binding to angiogenesis is also noted in other situations such as embryogenesis, where inhibition of b1 integrins interfere with the development of the embryonic vasculature(63) and in oncology, where integrin inhibitors are employed to inhibit tumor angiogenesis.(64)”
BackgroundAngiogenesis as a Novel Component of Inflammatory Bowel Disease Pathogenesis
Danese, S., Sans, M., de la Motte, C., Graziani, C., West, G., Phillips, M. H., Pola, R., Rutella, S., Willis, J., Gasbarrini, A., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.054 · Cited by 374
In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts
Chen, X., Conti, P. S., & Moats, R. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1956 · Cited by 347
Metadata
- Authors
- Kumar, C.
- Corresponding author
- Kumar, C.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-02-01
- Volume
- 4
- Issue
- 2
- Pages
- 123-131
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W147592962
- Cited by
- 280
- References
- 0
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 6 · 2022: 14 · 2021: 4 · 2020: 9 · 2019: 11 · 2018: 8 · 2017: 9 · 2016: 8 · 2015: 11 · 2014: 11 · 2013: 20 · 2012: 20
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Keywords
- integrin αvβ3, tumor angiogenesis, angiogenesis inhibitors, monoclonal antibodies, small molecule antagonists, angiostatin, endostatin, tumstatin, tumor growth, metastasis, bone metastasis, osteoclast resorption, rheumatoid arthritis, osteoporosis, therapeutic target
- MeSH terms
- Animals, Humans, Neoplasms, Neovascularization, Pathologic, Drug Delivery Systems, Angiogenesis Inhibitors, Integrin alphaVbeta3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.